State‐of‐the‐Art Clinical Article: Pharmacokinetic/Pharmacodynamic Parameters: Rationale for Antibacterial Dosing of Mice and Men
The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Investigations over the past 20 years have demonstrated that antibacterials can vary markedly in the time course of antimicrobial activity. These differences in pharmacodynamic activity have implications for optimal dosage regimens. The results of more recent studies suggest that the magnitude of the pharmacokinetic/pharmacodynamic parameters required for efficacy are relatively similar in animal infection models and in human infections. However, there is still much to learn. Additional studies are needed to further correlate pharmacokinetic/pharmacodynamic parameters for many antibacterials with therapeutic efficacy in a variety of animal infection models and in human infections. The potential value of using pharmacokinetic/pharmacodynamic parameters as guides for establishing optimal dosing regimens for new and old drugs and for new emerging pathogens and resistant organisms, for setting susceptibility breakpoints, and for reducing the cost of drug development should make the continuing search for the therapeutic rationale of antibacterial dosing of mice and men worthwhile.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Moore, R. D., Lietman, P. S., & Smith, C. R. (1987) · Journal of Infectious Diseases · doi:10.1093/infdis/155.1.93 · Cited by 1,139 · cited 1×
“However, the opposite was observed in the major clinical trials correlating pharmacokinetic/pharmacodynamic parameters with the therapeutic efficacy of aminoglycosides [56].”
Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients
Forrest, A., Nix, D. E., Ballow, C. H., Goss, T. F., Birmingham, M. C., & Schentag, J. J. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.5.1073 · Cited by 1,101 · cited 2×
“[52] found that a 24-hour AUC/MIC value of > 125 was associated with satisfactory outcome for seriously ill patients treated with intravenous ciprofloxacin.”
Pallares, R., Liñares, J., Vadillo, M., Cabellos, C., Manresa, F., Viladrich, P. F., Martin, R., & Gudiol, F. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508243330802 · Cited by 773
Correlation of Antimicrobial Pharmacokinetic Parameters with Therapeutic Efficacy in an Animal Model
Vogelman, B., Gudmundsson, S., Leggett, J., Turnidge, J., Ebert, S., & Craig, W. A. (1988) · The Journal of Infectious Diseases · doi:10.1093/infdis/158.4.831 · Cited by 720 · cited 3×
“need to exceed the MIC for 100% of the dosing interval to exert a significant antibacterial effect [25-27, 36].”
Self-citationCraig, W. A. (1995) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/0732-8893(95)00053-d · Cited by 618 · cited 5×
“Several investigators have used multiple dosage regimens in animal infection models to correlate specific pharmacokinetic/pharmacodynamic parameters with the efficacy of various antibacterials against both gram-positive and gram-negative bacilli [9, 25-31].”
InfluentialSelf-citationBlaser, J., Stone, B. B., Groner, M. C., & Zinner, S. H. (1987) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.31.7.1054 · Cited by 481
Pharmacokinetics and pharmacodynamics of antibiotics in otitis media
CRAIG, W. A., & ANDES, D. (1996) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-199603000-00015 · Cited by 435 · cited 3×
“pneumoniae and Haemophilus influenzae in patients with otitis media [38, 43].”
InfluentialSelf-citationDrusano, G. L., Johnson, D. E., Rosen, M., & Standiford, H. C. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.3.483 · Cited by 426 · cited 2×
“there is a significant risk of the emergence of resistant subpopulations [29].”
Leggett, J. E., Fantin, B., Ebert, S., Totsuka, K., Vogelman, B., Calame, W., Mattie, H., & Craig, W. A. (1989) · Journal of Infectious Diseases · doi:10.1093/infdis/159.2.281 · Cited by 354
Self-citationKinetics of antimicrobial activity
Vogelman, B., & Craig, W. A. (1986) · The Journal of Pediatrics · doi:10.1016/s0022-3476(86)80754-5 · Cited by 315 · cited 4×
“PAE refers to the persistent suppression of bacterial growth following exposure to an antimicrobial [2, 7, 10].”
InfluentialSelf-citation
Cited by
Items 701–800 of 1,003
Appropriate Antibiotic Therapy
Allison, M. G., Heil, E. L., & Hayes, B. D. (2016) · Emergency Medicine Clinics of North America · doi:10.1016/j.emc.2016.08.003 · Cited by 51
Sime, F. B., Lassig‐Smith, M., Starr, T., Stuart, J., Pandey, S., Parker, S. L., Wallis, S. C., Lipman, J., & Roberts, J. A. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01265-19 · Cited by 51
Marín, P., Escudero, E., Fernández-Varón, E., & Cárceles, C. M. (2007) · Journal of Dairy Science · doi:10.3168/jds.2007-0071 · Cited by 51
“Previous investigations have shown that, for fluoroquinolones, a Cmax/MIC90 ratio >3 produced 99% reduction in bacterial count, and a Cmax/MIC90 ratio of ≥8 prevented the emergence of resistant microorganisms (Craig, 1998).”
BackgroundImipenem Levels Are Not Predictable in the Critically Ill Patient
Belzberg, H., Zhu, J., Cornwell, E. E., Murray, J., Sava, J. A., Salim, A., Velmahos, G. C., & Gill, M. A. (2004) · The Journal of Trauma: Injury, Infection, and Critical Care · doi:10.1097/01.ta.0000056164.26493.28 · Cited by 51
Schulte, S., Ackermann, T., Bertram, N., Sauerbruch, T., & Paar, W. D. (2006) · Journal of Chromatographic Science · doi:10.1093/chromsci/44.4.205 · Cited by 51
Lee, D., Murakami, Y., Andes, D. R., & Craig, W. A. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00362-12 · Cited by 51
Self-citationLauritzen, B., Lykkesfeldt, J., & Friis, C. (2003) · Research in Veterinary Science · doi:10.1016/s0034-5288(03)00029-8 · Cited by 51
Impact of pharmacodynamics on breakpoint selection for susceptibility testing
Mouton, J. W. (2003) · Infectious Disease Clinics of North America · doi:10.1016/s0891-5520(03)00062-x · Cited by 51
“It seems that the effect of declining concentrations over time is fundamentally different for various classes of antibiotics, and is in most cases directly related to the pattern of antimicrobial activity [8].”
BackgroundInfluence of pharmacokinetic and pharmacodynamic principles on antibiotic selection
Zhanel, G. G. (2001) · Current Infectious Disease Reports · doi:10.1007/s11908-001-0056-x · Cited by 51
Couffignal, C., Pajot, O., Laouenan, C., Burdet, C., Foucrier, A., Wolff, M., Armand-Lefèvre, L., Mentré, F., & Massias, L. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12435 · Cited by 50
“The median duration of stay in the ICU and of mechanical ventilation before inclusion was 8 days [1-60] and 8 days [5-60], respectively.”
BackgroundGiachetto, G., Telechea, H., Speranza, N., Oyarzun, M., Nanni, L., & Menchaca, A. (2010) · Pediatric Critical Care Medicine · doi:10.1097/pcc.0b013e3181fe4047 · Cited by 50
“In animal models it has been shown that the relationship between area under the curve in 24 hrs and MIC (AUC24/ MIC) predicts antimicrobial efficacy of vancomycin (17, 19).”
BackgroundPharmacokinetic-Pharmacodynamic-Model-Guided Doripenem Dosing in Critically Ill Patients
Samtani, M. N., Flamm, R. K., Kaniga, K., & Nandy, P. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01843-09 · Cited by 50
“pected when T MIC exceeds 20 and 40, respectively (9, 12).”
BackgroundZhao, M., Lepak, A. J., Marchillo, K., VanHecker, J., & Andes, D. R. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00250-17 · Cited by 50
Adembri, C., & Novelli, A. (2009) · Clinical Pharmacokinetics · doi:10.2165/10895960-000000000-00000 · Cited by 50
“The relative importance of the three pharmacokinetic/pharmacodynamic parameters varies according to different antimicrobial classes, and sometimes overlaps.([12-14,21]) In experimental models, the three main pharmacokinetic/ pharmacodynamic parameters can be studied almost independently by creating conditions that red…”
BackgroundRoberts, J. K., Stockmann, C. R., Constance, J. E., Stiers, J., Spigarelli, M. G., Ward, R. M., & Sherwin, C. M. T. (2014) · Clinical Pharmacokinetics · doi:10.1007/s40262-014-0147-0 · Cited by 50
“administered infrequently [20].”
Smith, P. (2006) · Aquaculture · doi:10.1016/j.aquaculture.2006.05.027 · Cited by 50
Moriyama, B., Henning, S. A., Neuhauser, M. M., Danner, R. L., & Walsh, T. J. (2009) · Annals of Pharmacotherapy · doi:10.1345/aph.1l638 · Cited by 50
The Changing Face of Antibiotic Prescribing: The Mutant Selection Window
Epstein, B. J., Gums, J. G., & Drlica, K. (2004) · Annals of Pharmacotherapy · doi:10.1345/aph.1e041 · Cited by 50
Future directions in the management of tertiary peritonitis
Buijk, S. L. C. E., & Bruining, H. A. (2002) · Intensive Care Medicine · doi:10.1007/s00134-002-1383-6 · Cited by 50
“Greater attention paid to the pharmacodynamic properties of these different groups of antibiotics has resulted in higher efficacy and less antimicrobial resistance in both in vivo and in vitro models [ 41 ].”
BackgroundLal, A., Jaoude, P., & El-Solh, A. A. (2016) · Infection & Chemotherapy · doi:10.3947/ic.2016.48.2.81 · Cited by 44
“Despite our better understanding of the mechanisms underlying NP, successful treatment of these patients remains a difficult and complex undertaking as it is influenced by various factors such as lack of a gold standard for definitive diagnosis of NP, difficulty in differentiating colonization from active infection, f…”
BackgroundMutant Prevention Concentration of Gemifloxacin for Clinical Isolates of Streptococcus pneumoniae
Hansen, G. T., Metzler, K., Drlica, K., & Blondeau, J. M. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.1.440-441.2003 · Cited by 50
“Since the effectiveness of an antibacterial agent is likely to be a function of both activity (MIC and MPC) and pathogen exposure (5, 11), comparision of compounds requires consideration of drug pharmacokinetics in human tissues.”
BackgroundIkawa, K., Morikawa, N., Sakamoto, K., Ikeda, K., Ohge, H., Takesue, Y., & Sueda, T. (2008) · Chemotherapy · doi:10.1159/000118665 · Cited by 49
“For imipenem, the T > MIC target value in humans is unknown, and it is not easy to establish because therapeutic effects are greatly influenced by host factors such as severity of disease and status of immune system. However, the T > MIC targets required for bacteriostatic and bactericidal effects in animals are consi…”
BackgroundA Review of Levofloxacin for the Treatment of Bacterial Infections
Noel, G. J. (2009) · Clinical Medicine Therapeutics · doi:10.4137/cmt.s28 · Cited by 49
Curis, E., Pestre, V., Jullien, V., Eyrolle, L. J., Archambeau, D., Morand, P., Gatin, L., Karoubi, M., Pinar, N., Dumaine, V., et al. (2015) · Infection · doi:10.1007/s15010-015-0773-y · Cited by 50
Rodríguez, C. A., Agudelo, M., Zuluaga, A. F., & Vesga, Ó. (2010) · BMC Infectious Diseases · doi:10.1186/1471-2334-10-153 · Cited by 49
“To optimize the pharmacodynamic (PD) index predicting efficacy for β-lactams (time above MIC), treatment was administered q1h by 0.2 mL subcutaneous injections [ 10 ].”
MethodInfluentialMeropenem in the treatment of complicated skin and soft tissue infections
Fish, D. N. (2006) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.2006.2.4.401 · Cited by 49
“A ≥ 30% T>MIC is associated with bacteriostatic activity of the carbapenems, while a ≥ 40% T>MIC is more predictably bactericidal and associated with prevention of the development of resistance (Craig 1998; Turnidge 1998).”
The new treatment paradigm and the role of carbapenems
Masterton, R. G. (2008) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2008.07.023 · Cited by 49
Lonsdale, D. O., Udy, A. A., Roberts, J. A., & Lipman, J. (2012) · Journal of neurosurgery · doi:10.3171/2012.10.jns12883 · Cited by 49
Usman, M. A., Frey, O. R., & Hempel, G. (2016) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-016-2172-4 · Cited by 49
“For optimal antibacterial activity, 40% T > MIC should be achieved [5, 6]; however, providing the fact that plasma concentrations of 4–5 folds greater than MIC are associated with bactericidal activity, recent studies suggested Electronic supplementary material The online version of this article (doi:10.”
BackgroundSecond-line rescue treatment of Helicobacter pylori infection: Where are we now?
Lin, T., & Hsu, P. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i40.4548 · Cited by 49
on behalf the ATB PK/PD study group, Pilmis, B., Petitjean, G., Lesprit, P., Lafaurie, M., Helali, N. E., & Monnier, A. L. (2019) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-019-03573-4 · Cited by 49
Matsumoto, T. (2014) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s44377 · Cited by 49
“43 It was shown that the probability of cure/improvement rose when the C max of ABK was increased, with an odds ratio of 6.7 for a change in C max from 7.9–12.5 µ g/mL. 44 48”
InfluentialAntifungal effects of Ellagitannin isolated from leaves of Ocotea odorifera (Lauraceae)
Yamaguchi, M. U., Garcia, F. P., Cortez, D. A. G., Ueda‐Nakamura, T., Filho, B. P. D., & Nakamura, C. V. (2010) · Antonie van Leeuwenhoek · doi:10.1007/s10482-010-9516-3 · Cited by 49
“…plants have been the source of innumerable phytochemical molecules with antimicrobial activity in vitro, but in order to be therapeutically useful, a substance must inhibit the infecting microorganism and exhibit greater selective toxicity towards it than towards the host cell (Craig 1998).”
BackgroundSpeculative strategies for new antibacterials: all roads should not lead to Rome
Shapiro, S. (2013) · The Journal of Antibiotics · doi:10.1038/ja.2013.27 · Cited by 49
Laohavaleeson, S., Tessier, P. R., & Nicolau, D. P. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01422-07 · Cited by 49
“While other cephalosporin antibiotics require fT MICs of approximately 30 to 40% for stasis or 60 to 70% for bactericidal effects (11), our study demonstrated that BPR exerted consistent killing activity against diversely resistant S.”
BackgroundMurillo, Ó., Pachón, M. E., Euba, G., Verdaguer, R., Tubau, F., Cabellos, C., Cabo, J., Gudiol, F., & Ariza, J. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00458-08 · Cited by 49
“parameters in TCF were close to those in human serum (12, 43); area under the”
ResultTherapeutic Drug Monitoring of Antibiotics: Defining the Therapeutic Range.
Abdul-Aziz, M. H., Brady, K., Cotta, M. O., & Roberts, J. A. (2022) · PubMed · doi:10.1097/ftd.0000000000000940 · Cited by 48
“%) of fT.MIC.25 Copyright © 2021 Wolters Kluwer Health, Inc.”
BackgroundInfluentialLodise, T. P., & Low, D. E. (2012) · Drugs · doi:10.2165/11635660-000000000-00000 · Cited by 48
Muller, A. E., Punt, N. C., & Mouton, J. W. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02611-13 · Cited by 48
“This has similarly been described for other antibiotics (3).”
BackgroundZheng, S., Matzneller, P., Zeitlinger, M. A., & Schmidt, S. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02904-14 · Cited by 48
Eto, H., Suzuki, S., Kusano, C., Ikehara, H., Ichijima, R., Ito, H., Kawabe, K., Kawamura, M., Yoda, Y., Nakahara, M., et al. (2021) · Helicobacter · doi:10.1111/hel.12788 · Cited by 48
Heffernan, A. J., Lim, S. M. S., Lipman, J., & Roberts, J. A. (2021) · Anaesthesia Critical Care & Pain Medicine · doi:10.1016/j.accpm.2021.100970 · Cited by 48
Mirzaei, R., Yousefimashouf, R., Arabestani, M. R., Sedighi, I., & Alikhani, M. Y. (2022) · PLoS ONE · doi:10.1371/journal.pone.0277287 · Cited by 48
Doðan, H., & Aydin, S. (2013) · African Journal of Traditional Complementary and Alternative Medicines · doi:10.4314/ajtcam.v10i4.9 · Cited by 48
“According to Craig (1998), to evaluate antimicrobial activity, MIC values should be measured from the 4th through the 16th dilutions.”
BackgroundCrandon, J. L., Banevicius, M. A., & Nicolau, D. P. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00647-08 · Cited by 48
“To date, the sparse data available for tetracyclines as a class seem to suggest that the AUC/MIC is the pharmacodynamic parameter most associated with antibacterial activity (3).”
BackgroundKatsube, T., Yamano, Y., & Yano, Y. (2007) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21062 · Cited by 48
Bernard, A., Kermarrec, G., Parize, P., Caruba, T., Bouvet, A., Mainardi, J., Sabatier, B., & Nich, C. (2015) · Journal of Infection · doi:10.1016/j.jinf.2015.03.013 · Cited by 48
Pharmacokinetics and Pharmacodynamics: Optimal Antimicrobial Therapy in the Intensive Care Unit
Lodise, T. P., & Drusano, G. L. (2010) · Critical Care Clinics · doi:10.1016/j.ccc.2010.11.003 · Cited by 48
Lepak, A., Nett, J., Lincoln, L., Marchillo, K., & Andes, D. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.4.1311-1319.2006 · Cited by 42
“The time course of antimicrobial activity is dependent on a drug’s pharmacokinetics and two major pharmacodynamic characteristics (2, 13).”
BackgroundStreptococcus pneumoniae in the USA: in vitro susceptibility and pharmacodynamic analysis
Mason, E. O., Lamberth, L. B., Kershaw, N. L., Prosser, B. L., Zoe, A., & Ambrose, P. G. (2000) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/45.5.623 · Cited by 48
“2 530 (54) 258 (26) 197 (20) 46 2– 6 206 (60) 85 (25) 53 (15) 40 6– 12 131 (71) 36 (19) 18 (10) 29 12– 25 126 (69) 44 (24) 12 (7) 31 25– 65 915 (66) 327 (24) 139 (10) 34 65 839 (68) 266 (22) 128 (10) 32”
Wart, S. V., Phillips, L., Ludwig, E. A., Russo, R., Gajjar, D. A., Bello, A., Ambrose, P. G., Costanzo, C., Grasela, T. H., ECHOLS, R. M., et al. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.12.4766-4777.2004 · Cited by 48
“Ethnicity, n (%) Black 32 (6) 10 (7) Caucasian 492 (85) 117 (83) Hispanic 56 (10) 14 (10)”
BackgroundUse of the t > MIC to choose between different dosing regimens of beta-lactam antibiotics
Mouton, J. W., & Punt, N. (2001) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/47.4.500 · Cited by 48
“Sir, The major pharmacodynamic index correlating with in vitro and in vivo efficacy has been shown to be the time the concentration of an antibiotic remains above the MIC, or in short, the t MIC.(1) This relationship has been shown both in in vitro pharmacokinetic models and numerous animal experiments, and the analys…”
ResultKiffer, C. R. V., Mendes, C., Kuti, J. L., & Nicolau, D. P. (2004) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2004.03.003 · Cited by 48
Andes, D. R. (2001) · Current Opinion in Infectious Diseases · doi:10.1097/00001432-200104000-00010 · Cited by 48
Álvarez-Sala, J. L., Kardos, P., Martínez-Beltrán, J., Coronel, P., Aguilar, L., & the Cefditoren AECB Working Group (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.5.1762-1767.2006 · Cited by 48
“centrations in serum exceed the MIC for the pathogen is the key indicator of bacteriological efficacy, 35 to 40% of the time between two doses being the predictive value for maximal bacteriological efficacy (6, 25).”
BackgroundRamsamy, Y., Hardcastle, T. C., & Muckart, D. J. J. (2016) · World Journal of Surgery · doi:10.1007/s00268-016-3531-0 · Cited by 47
“Penicillin and monobactams are reported to require at least 50–60 % fT[MIC, cephalosporins need a 60–70 % fT[MIC, whereas carbapenems require a 40 % fT[MIC [9].”
BackgroundEl-Fateh, M., Chatterjee, A., & Zhao, X. (2024) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2024.107083 · Cited by 47
Zuluaga, A. F., Agudelo, M., Cardeño-Sánchez, J. J., Rodríguez, C. A., & Vesga, Ó. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010744 · Cited by 47
“2-mL subcutaneous injections to optimize Cmax/MIC and AUC/MIC, the pharmacodynamic (PD) indices associated with efficacy in mice and humans with normal renal function [21,22].”
BackgroundLepak, A. J., Marchillo, K., VanHecker, J., & Andes, D. R. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01717-15 · Cited by 47
“The results of these studies were analyzed by 59 using the sigmoid dose-effect model (32).”
MethodRoadmap for antibiotic discovery
Shore, C., & Coukell, A. J. (2016) · Nature Microbiology · doi:10.1038/nmicrobiol.2016.83 · Cited by 47
Jamieson, C., Allwood, M. C., Stonkute, D., Wallace, A., Wilkinson, A.-S., & Hills, T. (2019) · European Journal of Hospital Pharmacy · doi:10.1136/ejhpharm-2018-001699 · Cited by 47
Lepak, A. J., Wang, W., & Andes, D. R. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01517-20 · Cited by 47
“Pharmacokinetic/pharmacodynamic (PK/PD) studies are an integral step early in the drug development process (4).”
BackgroundPiperacillin-Tazobactam in Intensive Care Units: A Review of Population Pharmacokinetic Analyses
El‐Haffaf, I., Caissy, J.-A., & Marsot, A. (2021) · Clinical Pharmacokinetics · doi:10.1007/s40262-021-01013-1 · Cited by 47
“Although CI does appear to have a beneficial impact on clinical outcomes among ICU patients, many clinicians request more well-designed studies to be conducted before reaching a conclusion.”
BackgroundInfluentialBulitta, J. B., Kinzig, M., Jakob, V., Holzgrabe, U., Sörgel, F., & Holford, N. H. G. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03750.x · Cited by 47
Determinants of Ceftriaxone Clearance by Continuous Venovenous Hemofiltration and Hemodialysis
Matzke, G. R., Frye, R. F., Joy, M. S., & Palevsky, P. M. (2000) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.20.7.635.35170 · Cited by 47
Rodríguez-Martínez, J. M., Pichardo, C., García, I., Pachón-Ibáñez, M. E., Docobo-Pérez, F., Pascual, Á., Pachón, J., & Martínez-Martínez, L. (2008) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2008.02020.x · Cited by 47
“Several reports [18–21] indicate that in humans a 24-h area under the serum concentration time curve (AUC) ⁄MIC ratio of ‡25–30 for immunocompetent patients or ‡100–125 for immunocompromised patients and a serum peak concentration ⁄MIC ratio >8 are good indicators of a favourable outcome of quinolone treatment.”
BackgroundReview of Pharmacokinetics and Pharmacodynamics of Antimicrobial Agents
Estes, L. L. (1998) · Mayo Clinic Proceedings · doi:10.4065/73.11.1114 · Cited by 47
Slavik, R. S., & Jewesson, P. J. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342090-00002 · Cited by 47
In vitro pharmacodynamic characteristics of flucytosine determined by time-kill methods☆
Lewis, R. E., Klepser, M. E., & Pfaller, M. A. (2000) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(99)00125-x · Cited by 47
Pharmacodynamics of Antiinfective Therapy: Taking What We Know to the Patient's Bedside
Rodvold, K. A. (2001) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.21.18.319s.33904 · Cited by 47
“The likelihood of a successful clinical outcome correlates with specific pharmacodynamic parameters and antiinfective agents (Table 1).(2) b-Lactams, aminoglycosides, and fluoroquinolones represent the three classes of antiinfective agents for which we have made the most progress toward the clinical applications of ph…”
BackgroundFile, T. M., Lode, H. M., Kurz, H., Kozak, R., Xie, H., & Berkowitz, E. M. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.9.3323-3331.2004 · Cited by 47
“For amoxicillin-clavulanate, a time above MIC (T MIC) of 35 to 40% of the dosing interval is predictive of high bacteriological efficacy (3, 22).”
Azoulay-Dupuis, E., Bédos, J. P., Mohler, J., Schmitt‐Hoffmann, A. H., Schleimer, M., & Shapiro, S. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.4.1105-1111.2004 · Cited by 47
We can do better: a fresh look at echinocandin dosing
Bader, J. C., Bhavnani, S. M., Andes, D. R., & Ambrose, P. G. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx448 · Cited by 46
Daikos, G. L., Skiada, A., Pavleas, J., Vafiadi, C., Salatas, K., Tofas, P., Tzanetou, K., Markogiannakis, A., Thomopoulos, G., Vafiadi, I., et al. (2010) · Journal of Chemotherapy · doi:10.1179/joc.2010.22.3.175 · Cited by 46
Personalised dosing of medicines for children
Al‐Metwali, B. Z., & Mulla, H. (2017) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12709 · Cited by 46
“Moreover, the standard dosing regimens for antimicrobials are usually derived from studies in non-critically ill, ambulatory patients, so that when applied to critically ill patients, risks suboptimal drug exposure.([43]) Marked between-patient variability in PK is characteristic of critically ill patients and may res…”
BackgroundZhang, M., Peltier, R., Zhang, M., Lu, H., Bian, H., Li, Y. Y., Xu, Z., Shen, Y., Sun, H., & Wang, Z. (2017) · Journal of Materials Chemistry B · doi:10.1039/c7tb00610a · Cited by 46
Dalbavancin Population Pharmacokinetic Modeling and Target Attainment Analysis
Carrothers, T. J., Chittenden, J. T., & Critchley, I. A. (2019) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.695 · Cited by 46
Sou, T., Hansen, J. U., Liepinsh, E., Backlund, M., Ercan, O., Grīnberga, S., Cao, S., Giachou, P., Petersson, A., Tomczak, M., et al. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2104 · Cited by 46
Roos, J. F., Lipman, J., & Kirkpatrick, C. M. J. (2007) · Intensive Care Medicine · doi:10.1007/s00134-007-0573-7 · Cited by 46
“In vivo animal models of infection [5] have demonstrated that for β-lactams f T>MIC of about 60–70% is required to achieve near-maximal bacterial killing.”
BackgroundBurgess, D. S., Frei, C. R., Lewis, J. S., Fiebelkorn, K. R., & Jorgensen, J. H. (2006) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2006.01617.x · Cited by 46
“Gramnegative bacteria should be 100–125 [36,37].”
Cock, P. A. J. G. D., Mulla, H., Desmet, S., Somer, F. M. J. J. D., McWhinney, B. C., Ungerer, J. P. J., Moerman, A., Commeyne, S., Walle, J. V., François, K., et al. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw496 · Cited by 46
Sethi, S., Breton, J., & Wynne, B. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.1.153-160.2005 · Cited by 46
“For -lactam antimicrobials, the time above MIC (T MIC) of the infecting pathogen is the key indicator for predicting bacteriological efficacy, and for amoxicillin and amoxicillin-clavulanate, a T MIC of 35 to 40% of the dosing interval is predictive of maximum bacteriological efficacy (8, 9, 10, 23, 32).”
BackgroundPharmacodynamics to combat resistance
Woodnutt, G. (2000) · Journal of Antimicrobial Chemotherapy · doi:10.1093/oxfordjournals.jac.a020890 · Cited by 46
Cousson, J., Floch, T., Guillard, T., Vernet, V., Raclot, P., Wolak‐Thierry, A., & Jolly, D. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04232-14 · Cited by 45
“The pharmacodynamic property that predicts better clinical efficacy in vitro is the time during which the tissue concentration of the antibiotic is greater than the MIC of the organism (1, 2).”
BackgroundMethodWoksepp, H., Hällgren, A., Borgström, S., Kullberg, F., Wimmerstedt, A., Oscarsson, A., Nordlund, P., Lindholm, M.-L., Bonnedahl, J., Brudin, L. H., et al. (2016) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-016-2832-4 · Cited by 45
“On the other hand, this may be favorable in order to avoid the development of antibiotic resistance, as targets of 100% fT>4×MIC have been discussed [9].”
BackgroundRamos, J. R., Ramírez, P., Gordón, M., Villarreal, E., Concha, P., Aroca, M. J. C., Frasquet, J., Miñana, M. R. M., & Castellanos-Ortega, Á. (2017) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2017.09.019 · Cited by 45
Masich, A. M., Heavner, M. S., Gonzales, J. P., & Claeys, K. C. (2018) · Current Infectious Disease Reports · doi:10.1007/s11908-018-0613-1 · Cited by 45
Lepak, A. J., Zhao, M., & Andes, D. R. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01648-19 · Cited by 45
Population Pharmacokinetics and Pharmacodynamics of Meropenem in Critically Ill Pediatric Patients
Saito, J., Shoji, K., Oho, Y., Kato, H., Matsumoto, S., Aoki, S., Nakamura, H., Ogawa, T., Hasegawa, M., Yamatani, A., et al. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01909-20 · Cited by 45
“A fixed 2% fu of MEM was used for simulations, according to previously reported data (9).”
BackgroundMethodCavallo, J.-D., Fabré, R., Jehl, F., Rapp, C., & Garrabé, É. (2004) · EMC-Maladies infectieuses/Encyclopédie médico-chirurgicale. Maladies infectieuses · doi:10.1016/j.emcmi.2004.03.003 · Cited by 45
Cefepime Dosing in the Morbidly Obese Patient Population
Rich, B. S., Keel, R. A., Ho, V. P., Turbendian, H. K., Afaneh, C. I., Dakin, G. F., Pomp, A., Nicolau, D. P., & Barie, P. S. (2012) · Obesity Surgery · doi:10.1007/s11695-011-0586-8 · Cited by 45
Antibacterial Agents in Pediatrics
Chávez‐Bueno, S., & Stull, T. L. (2009) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2009.06.011 · Cited by 45
“Such antibiotics as b-lactams, vancomycin, clindamycin, and macrolides demonstrate time-dependent killing (ie, longer time with the drug concentration above the minimum inhibitory concentration (MIC) of the target organism increases bacterial killing) [3].”
Errico, J. A., Trumble, T. N., Bueno, A. C. D., Davis, J. L., & Brown, M. P. (2008) · American Journal of Veterinary Research · doi:10.2460/ajvr.69.3.334 · Cited by 45
“Drug concentrations of 10 times the MIC appear to be generally accepted as the minimum Cmax:MIC necessary to result in pure concentration-dependent killing for these agents.(4) The goal of treatment with aminoglycosides should be optimization of peak concentrations by use of the highest possible nontoxic dose.”
BackgroundSabet, M., Miller, C. E., Nolan, T. G., Senekeo‐Effenberger, K., Dudley, M. N., & Griffith, D. C. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00268-09 · Cited by 45
“While fluoroquinolones (MP-376, levofloxacin) and aminoglycosides (tobramycin) have concentration-dependent antibacterial effects (Cmax/MIC or AUC/MIC), monobactams like aztreonam have time-dependent antibacterial effects; thus, the percentage of the dosing interval during which the concentrations exceed the MIC is li…”
BackgroundLandersdorfer, C. B., Kinzig, M., Bulitta, J. B., Hennig, F. F., Holzgrabe, U., Sörgel, F., & Gusinde, J. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01119-08 · Cited by 45
“fT MIC of 30% was shown to be the PK-PD target for the bacteriostasis of penicillins on the basis of the concentrations in plasma (16, 19).”
BackgroundSingle-dose daptomycin pharmacokinetics in chronic haemodialysis patients
Salama, N. N., Segal, J. H., Churchwell, M. D., Patel, J. H., Gao, L., Heung, M., & Mueller, B. A. (2009) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfp655 · Cited by 45
Bulik, C. C., Okusanya, Ó. O., Lakota, E. A., Forrest, A., Bhavnani, S. M., Hoover, J. L., Andes, D. R., & Ambrose, P. G. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00115-16 · Cited by 45
“25 The PAE of an antibiotic, which can be evaluated using either in vitro or in vivo 489 methods, can be described as the persistent suppression of the growth of the pathogen 490 following exposure to the antibiotic [27].”
MethodClinical utility of antifungal pharmacokinetics and pharmacodynamics
Andes, D. (2004) · Current Opinion in Infectious Diseases · doi:10.1097/00001432-200412000-00005 · Cited by 45
The pharmacokinetics of orbifloxacin in the horse following oral and intravenous administration
Davis, J. L., Papich, M. G., & Weingarten, A. J. (2006) · Journal of Veterinary Pharmacology and Therapeutics · doi:10.1111/j.1365-2885.2006.00737.x · Cited by 45
Kerrn, M. B., Frimodt‐Møller, N., & Espersen, F. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.3.1002-1009.2003 · Cited by 45
“Several other studies with animal infection models showed that for -lactam antibiotics, if the time for which levels in serum exceeded the MIC was greater than 40%, the survival or bacteriologic cure rate was about 85 to 100% (7).”
Background
Metadata
- Authors
- Craig, W. A.
- Affiliations
- William S. Middleton Memorial Veterans Hospital (US)
- Corresponding author
- Craig, William A.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 1998-01
- Volume
- 26
- Issue
- 1
- Pages
- 1-10
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2113717321
- Cited by
- 2,908
- References
- 50
- Citations by year
- 2026: 68 · 2025: 81 · 2024: 82 · 2023: 99 · 2022: 86 · 2021: 89 · 2020: 103 · 2019: 94 · 2018: 105 · 2017: 124 · 2016: 136 · 2015: 113 · 2014: 129 · 2013: 109 · 2012: 101
- FWCI
- 54.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Keywords
- pharmacokinetics/pharmacodynamics, dosing regimen, pharmacodynamic parameters, pharmacokinetic parameters, animal models of infection, human infection, susceptibility breakpoints, antimicrobial resistance, emerging pathogens, drug development costs
- MeSH terms
- Animals, Anti-Bacterial Agents, Bacteria, Humans, Lactams, Microbial Sensitivity Tests, Fluoroquinolones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.